ResMed Ready To Supply Digital Answers To Health Care’s Demand Challenges
Executive Summary
ResMed’s respiratory device portfolio has put it front and center of the global medtech industry’s efforts to bring COVID-19 under control. UK and Ireland country manager Antoine Valterio tells In Vivo how the company rose to the challenge, and how providers are now seeing digital technologies in a new light.
You may also be interested in...
Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
The New Culture Club: UK NHS Goes Upstream For Care Delivery And Offers New Chances For Medtechs
Hopes are high for the NHS Long Term Plan’s ability to transform health-care delivery and make a potentially unsustainable service fit for the future. There are opportunities for diagnostics, devices and digital providers, but are the resources there to turn the Plan into a success story?
ResMed Continues To Build Digital-Medicine Business With $225M Acquisition Of Propeller Health
Propeller Health bills itself as a digital respiratory therapeutics company, providing a mobile platform that communicates with sensors on patients' inhaler devices to help them manage chronic obstructive pulmonary disease and asthma. This the second major acquisition ResMed has announced in the last month.